Ionis Pharmaceuticals IONS Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- Ionis Pharmaceuticals (IONS) reported deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost of $67.59M in Q4 2025.